Terlipressin vs placebo or no intervention
Serious adverse events: cardiovascular events · people with hepatorenal syndrome
Terlipressin may leads to higher serious cardiovascular adverse events compared with placebo or no intervention (low certainty).
1 finding from 1 review
- Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome 2017 · Cochrane Headline outcomes onlyRR 7.26 [1.7, 31.05]4 studies · 234 participantsLow